TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00750477

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: NEM
Description: see Treatment Arms

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator containing inactives
Study: NCT04574466

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem Management Plus
Description: Problem Management Plus (PM+) is a new, brief, psychological intervention program based on CBT techniques that are empirically supported and formally recommended by the WHO. The full protocol was developed by the WHO and the University of New South Wales, Australia. The manual involves the following empirically supported elements: problem solving plus stress management, behavioural activation, facing fears, and accessing social support. These elements have been recommended in recent WHO guidelines.
Study: NCT01379651

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Specific oral tolerance induction
Description: Specific oral tolerance induction consisted in the administration of increasing amounts of raw emulsion egg
Study: NCT04431206

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Oxytocin administered by IV infusion
Study: NCT01885884

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Embedded Supportive Care
Study: NCT03456336

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Treatment
Description: Infants assigned to the active treatment group will receive indomethacin or ibuprofen per their local site usual care dosing and schedule if the infant has a sPDA. The choice of indomethacin or ibuprofen will be left to the center, however, infants may only receive one or the other. If the infant receives both, it will be considered a protocol violation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Expectant Management
Description: Infants assigned to the expectant management group will receive indomethacin or ibuprofen if cardiopulmonary compromise occurs.
Study: NCT02511028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferumoxytol
Description: 510mg (17mL) IV
Study: NCT03815695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FT-4202/Placebo
Description: Participants will receive FT-4202/placebo and monitored for side effects while undergoing pharmacokinetics and pharmacodynamic studies
Study: NCT01170845

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sivelestat sodium hydrate
Description: saline or sivelestat sodium hydrate intravenously for 7 days starting the beginning of surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sivelestat sodium hydrate
Description: saline or sivelestat sodium hydrate intravenously for 7 days starting the beginning of surgery
Study: NCT04130932

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ergonomic flooring
Description: Specially designed flooring system to optimize ergonomics of participants
Study: NCT00734578

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPD503-AM
Description: SPD503 (Guanfacine Extended Release)-AM Optimized 1-4mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPD503-PM
Description: SPD503 (Guanfacine Extended Release)-PM Optimized 1-4mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to Guanfacine Hydrochloride Extended Release
Study: NCT02191670

Intervention type: DRUG
Intervention: METALYSE®
Description: weight-adjusted dosage as single bolus over 5 to 10 seconds
Study: NCT01825850

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemigliptin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemigliptin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irbesartan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irbesartan
Study: NCT03328364

Intervention type: DRUG
Intervention: enzalutamide
Description: oral

Intervention type: DRUG
Intervention: enzalutamide
Description: oral

Intervention type: DRUG
Intervention: docetaxel
Description: intravenous infusion
Study: NCT03643224

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiofrequency Ablation
Description: A procedure will be performed using a radiofrequency ablation catheter.
Study: NCT03703440

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active arm
Description: ≥3 group education sessions in addition to usual diabetes care, every 3 months for 12 months

Intervention type: OTHER
Group type: OTHER
Intervention: Control arm
Description: Usual diabetes care, every 3-month for 12 months
Study: NCT04274231

Intervention type: GENETIC
Intervention: different effection
Description: Analysis of the reasons for treatment

Intervention type: GENETIC
Intervention: different effection
Description: Analysis of the reasons for treatment
Study: NCT01893346

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAZ-AVI
Description: Single IV dose of Ceftazidime and Avibactam. Dosage regimen will vary depending on cohort.
Study: NCT02558348

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL3818
Description: Administered orally
Study: NCT04263324

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-hypnosis/self-care
Description: Learning phase of self-hypnosis/self-care.
Study: NCT03016819

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL3818
Description: Anlotinib (AL3818) 12 mg orally administered once daily in 21-day cycles (14 days on treatment, 7 days off treatment)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL3818
Description: Anlotinib (AL3818) 12 mg orally administered once daily in 21-day cycles (14 days on treatment, 7 days off treatment)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dacarbazine
Description: Dacarbazine 1000 mg/m2 as a 20-120 minute IV infusion on Day 1 of each 21-day treatment cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Description: Dacarbazine 1000 mg/m2 as a 20-120 minute IV infusion on Day 1 of each 21-day treatment cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dacarbazine
Description: Dacarbazine 1000 mg/m2 as a 20-120 minute IV infusion on Day 1 of each 21-day treatment cycle

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AL3818 or placebo
Description: AL3818 or placebo 12 mg orally administered once daily in 21-day cycles (14 days on treatment, 7 days off treatment)
Study: NCT01869855

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Subdural Drainage

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Subperiosteal Drainage
Study: NCT01509703

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High flow therapy
Description: Each patient is treated with nasal high flow at different flow rates (15, 30, 45L/min). The order of flow rates is randomized. Each flow rate will be used for 15 minutes. A wash out time of ten minutes is planned after each phase, during which the patient uses his his individual oxygen flow.
Study: NCT03471923

Intervention type: DIAGNOSTIC_TEST
Intervention: Neurological Examination
Description: The family members and healthy volunteers will undergo elements of the neurological examination during which the movement disorders neurologist will look specifically for the presence of cervical dystonia and other sensory abnormalities. If the subject is found to have cervical dystonia or any other sensory abnormalities, the subject will be excluded from the study.

Intervention type: DIAGNOSTIC_TEST
Intervention: Neurological Examination
Description: The family members and healthy volunteers will undergo elements of the neurological examination during which the movement disorders neurologist will look specifically for the presence of cervical dystonia and other sensory abnormalities. If the subject is found to have cervical dystonia or any other sensory abnormalities, the subject will be excluded from the study.

Intervention type: DIAGNOSTIC_TEST
Intervention: Assessment of Non-Motor Features
Description: All subjects will be assessed for four non-motor symptoms, including (1) spatial discrimination threshold, (2) temporal discrimination threshold, (3) vibration-induced illusion of movement, and (4) kinesthesia.

Intervention type: DIAGNOSTIC_TEST
Intervention: Assessment of Non-Motor Features
Description: All subjects will be assessed for four non-motor symptoms, including (1) spatial discrimination threshold, (2) temporal discrimination threshold, (3) vibration-induced illusion of movement, and (4) kinesthesia.
Study: NCT03815695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FT-4202/Placebo
Description: Participants will receive FT-4202/placebo and monitored for side effects while undergoing pharmacokinetics and pharmacodynamic studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FT-4202/Placebo
Description: Participants will receive FT-4202/placebo and monitored for side effects while undergoing pharmacokinetics and pharmacodynamic studies
Study: NCT03701113

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Milk-based protein matrix (MBPM)
Description: Ingestion of the Test Product at 10:00 pm, post-absorptive of the evening meal, each day for the 24 week period of intervention

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Habitual dietary behaviour
Description: Subjects to maintain habitual dietary behaviour for the 24 week intervention
Study: NCT04167163

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abaloparatide
Description: 18 month ABL treatment
Study: NCT03705403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darleukin
Description: The product name refers to the molecule structure, in fact, L19-IL2 is a recombinant fusion protein composed of two moieties: L19, a human monoclonal antibody fragment in the single chain Fv (scFv) format, bound via a flexible linker to IL2, the human cytokine Interleukin-2.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation
Description: Radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Radiotherapy
Study: NCT03815695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FT-4202/Placebo
Description: Participants will receive FT-4202/placebo and monitored for side effects while undergoing pharmacokinetics and pharmacodynamic studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FT-4202/Placebo
Description: Participants will receive FT-4202/placebo and monitored for side effects while undergoing pharmacokinetics and pharmacodynamic studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FT-4202/Placebo
Description: Participants will receive FT-4202/placebo and monitored for side effects while undergoing pharmacokinetics and pharmacodynamic studies
Study: NCT02960893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Troriluzole
Description: Randomization Phase: Neat (i.e., drug substance without excipients); loose filled capsule.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Drug: Placebo Randomization Phase: Matching placebo loose filled capsule.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Troriluzole
Description: Extension phase: Neat capsule or formulated capsule (i.e., drug substance with excipients).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Troriluzole
Description: Extension phase: Neat capsule or formulated capsule (i.e., drug substance with excipients).
Study: NCT04557735

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ravulizumab
Description: Weight-based doses of ravulizumab will be administered intravenously as a loading dose regimen followed by maintenance dosing every 4 or 8 weeks, depending upon weight.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Supportive Care
Description: Participants will receive medications, therapies, and interventions per standard hospital treatment protocols (unless specifically prohibited by the protocol).
Study: NCT03463785

Intervention type: OTHER
Intervention: cone beam computed tomography
Description: The CBCT data sets of both the Chinese and Dutch OSA patients will be obtained using a NewTom 5G CBCT system (QR systems, Verona, Italy), according to the standard imaging protocol. The OSA patients will be treated with mandibular advancement device.

Intervention type: OTHER
Intervention: cone beam computed tomography
Description: The CBCT data sets of both the Chinese and Dutch OSA patients will be obtained using a NewTom 5G CBCT system (QR systems, Verona, Italy), according to the standard imaging protocol. The OSA patients will be treated with mandibular advancement device.
Study: NCT04294225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Given PO
Study: NCT03471923

Intervention type: DIAGNOSTIC_TEST
Intervention: Assessment of Non-Motor Features
Description: All subjects will be assessed for four non-motor symptoms, including (1) spatial discrimination threshold, (2) temporal discrimination threshold, (3) vibration-induced illusion of movement, and (4) kinesthesia.
Study: NCT04686552

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: cinnamon
Description: 6 g of ground cinnamon
Study: NCT01729403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aleglitazar
Description: 150 mcg orally daily, 16 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: patients will continue on their existing dose and regimen of metformin (but not more than the maximum dose specified in the label)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: metformin
Description: patients will continue on their existing dose and regimen of metformin (but not more than the maximum dose specified in the label)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: orally daily, 16 weeks
Study: NCT00714896

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stepped-Care
Description: * stage-based expert system written intervention at baseline and 3 months~* in-person stage appropriate counseling at baseline and 3 months~* telephone counseling sessions at weeks 2,4 and 8,~* as-needed brief check-in calls on or 2 days after quit date for those who have set a quit date; and/or check-in calls on days with anticipated high risk situations for former smokers or those who have quit smoking during the study~* optional NRT nicotine replacement therapy in the forms of patch, gum or lozenge for current smokers who are ready to quit smoking and/or for former smokers who report significantly strong smoking urges

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control
Description: Referral list to smoking cessation classes at Kaiser and the California Smokers Helpline
Study: NCT03684967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fruquintinib
Description: Fruquintinib treatment: 4mg in the Cycle 1,administration for 3 weeks followed by 1 week break, and administration every day for the first 21 days.5mg ,administration for 3 weeks followed by 1 week break, and administration every day for the first 21 days
Study: NCT01357148

Intervention type: DRUG
Intervention: Sitagliptin Phosphate/Metformin HCl (JANUMET®)
Description: Participants prescribed Sitagliptin Phosphate/Metformin HCl (JANUMET®) in routine clinical practice.
Study: NCT01140399

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Furosemide or Furosemide and Dopamine
Description: Patients randomized to pharmacological treatment receive~* either intravenous diuretics at escalating doses up to 20 mg/h~* or intravenous diuretics up to 20 mg/h and dopamine infusion at a constant rate of 3 mcg/Kg/m.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrafiltration
Description: All loop diuretics will be discontinued. Rate of fluid removal will be based on the extent of fluid overload as assessed by increase in body weight vs the patient's known dry weight~* less than 3 kg 200 ml/h~* more than 3 kg and less than 5 kg 300 mlh~* more than 5 kg 500 mlh~Criteria for achievement of target UF goals are removal of \> 50% and \<70% of fluid excess based on the estimated increase in body weight Diuretic infusion is allowed provided that a minimum of 3 hours after the end of the UF session have elapsed, at a maximum cumulative dose of 100 mg furosemide, till start of the next UF session The use of inotropic agents is prohibited
Study: NCT02709291

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: behavioral parent training
Description: Parents receive up to 6 sessions of the Family Check-Up program

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: interventionist training
Description: Interventionists are trained in the delivery of the Family Check-Up program and deliver sessions to families in their community
Study: NCT02195440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRI-724
Description: 10 - 160 mg/m2, 7 days CIV (in the vein) with 7 days rest per one cycle. Number of Cycles: 6.
Study: NCT03806998

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketoacids
Description: Provision of 1 Tablet containing 630 mg of ketoacids every 5 kg of body weight during 16 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Provision of placebo capsules similar to active supplement
Study: NCT00897104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rizatriptan benzoate (MK0462)
Description: single dose 5 mg rizatriptan p.o.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: sumatriptan
Description: single dose 50 mg sumatriptan p.o.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: Placebo to rizatriptan or sumatriptan, single dose placebo tablet taken orally
Study: NCT03709979

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: C-MAC videolaryngoscope
Description: An intubating device that is used for endotracheal intubation. Endotracheal intubation will be performed by anesthesiologist with C-MAC videolaryngoscope

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: C-MAC videolaryngoscope
Description: An intubating device that is used for endotracheal intubation. Endotracheal intubation will be performed by anesthesiologist with C-MAC videolaryngoscope
Study: NCT03781037

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GIVE Module
Description: The GIVE Module is a brief cognitive behavioral intervention targeting youths' beliefs that they are a burden or drain on others. It consists of two sessions embedded within a larger CBT protocol for anxiety or depression.
Study: NCT00394524

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Glucommander
Description: Glucommander is a Computer-guided Intravenous (IV) insulin infusion protocol used for glycemic control in inpatients. This algorithm directs the administration of IV insulin in response to Blood Glucose (BG) measurement at the patient's bedside. In this study, the Glucommander program was loaded into a PalmOne (Zire 31, Tungsten E2 by Palm Inc.) handheld personal digital assistant (PDA) device. During the infusion, the nurse entered BG levels into the system and the computer recommended the insulin infusion rate and a variable time to check the next glucose testing. An alarm prompted the scheduled glucose check. The insulin infusion followed the formula: Insulin/Hour = Multiplier × (BG- 60).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard insulin infusion algorithm
Description: Standard insulin infusion Algorithm is a standard paper form insulin infusion algorithm. The algorithm is divided into four columns based on empirically determined insulin sensitivity. The first column was for the most insulin-sensitive patients, and the fourth column was for the most insulin resistant patients. The majority of patients are started in the algorithm 1 column. Insulin resistant patients, such as those receiving glucocorticoids or receiving \>80 units of insulin per day as outpatients, started in the algorithm 2 column. The insulin infusion rate was determined by the patient's BG level and was measured hourly until the patient was stable and within the target range. If BG targets were not achieved and the BG had not decreased by at least 60 mg/dL in the preceding hour, the patient was moved to the next column.
Study: NCT00525798

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SMC021 Oral calcitonin
Description: 0.8mg SMC021 - oral calcitonin, once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SMC021 Placebo
Description: SMC021 - Placebo, once daily
Study: NCT03241940

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Chimeric Antigen Receptor T-Cell Therapy
Description: Given CD19/CD22-CAR T cells IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies